Novavax Inc DEFA14A, filed Jul 7, 2023
Novavax Inc (NVAX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
| o | Preliminary Proxy Statement |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| o | Definitive Proxy Statement |
| x | Definitive Additional Materials |
| o | Soliciting Material Pursuant to §240.14a-12 |
NOVAVAX, INC.
(Name of registrant as specified in its charter)
(Name of person(s) filing proxy statement, if other than the registrant)
Payment of Filing Fee (Check all boxes that apply):
| x | No fee required. |
| o | Fee paid previously with preliminary materials. |
| o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
The following communication was made available by Novavax, Inc. on Twitter and LinkedIn on July 7, 2023:
Your vote is important! Please remember to vote ahead of the upcoming Annual Meeting of Stockholders. Voting remains open until July 10, 2023, 11:59pm EST. Open the link for event details, 2022 Annual Report, and 2023 Proxy Statement: https://lnkd.in/gViPDYwe
Stockholders will need the control number that they received via mail or email in order to vote. Voting options:
Internet: www.proxyvote.com
Phone: 1-800-690-6903
